Laurus Labs (BOM:540222) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 23, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:540222 Laurus Labs Ltd BOM:540222
66 GF Score
Price ₹1,577.65
GF Value ₹706.86
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Laurus Labs Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Laurus Labs's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

BOM:540222 vs ZTS, UTHR: Margin of Safety % (DCF Dividends Based) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Laurus Labs's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Laurus Labs Margin of Safety % (DCF Dividends Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laurus Labs's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Laurus Labs's Margin of Safety % (DCF Dividends Based) falls into.


BOM:540222
66GF Score
Laurus Labs Ltd BOM:540222
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Laurus Labs (BOM:540222) Overvalued in 2026?

Based on GuruFocus' analysis, Laurus Labs stock appears to be overvalued. The current stock price of ₹1,577.65 is trading 123.2% above its estimated GF Value™ of ₹706.86. GuruFocus considers Laurus Labs to be Significantly Overvalued.

Key valuation signals for BOM:540222:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: ₹706.86 vs. price of ₹1,577.65 (123.2% above fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the BOM:540222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laurus Labs Business Description

Other Exchanges LAURUSLABS:India
Address Road No.1, Jubilee Hills, Plot No.103, Hyderabad, TG, IND, 500033
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. The company generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.
66GF Score

Get the complete analysis for BOM:540222

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,577.65
Price
₹706.86
GF Value